Background/Objectives: This systematic review aimed to comprehensively evaluate the role of spirituality and religion in the journey of patients with cancer and assess their impact on various aspects of well-being and coping mechanisms. Methods: Systematic searches were conducted in PubMed, Scopus, and Google Scholar following the PRISMA guidelines. This study focused on the period from 2014 to 2024, the time chosen for the emerging integration of spirituality and religion in cancer treatment. Inclusion criteria targeted studies exploring the impact of spirituality and religion on cancer patients’ quality of life, coping, and treatment outcomes. Results: A comprehensive search initially yielded 2591 papers, of which 1544 were excluded as duplicates, and 113 were further excluded based on the inclusion criteria. Ultimately, 53 papers were selected for review, including 8 prospective cohort, 17 cross-sectional, 16 observational descriptive, and 12 RCT studies. Encompassing 13,590 patients with various cancer types, including breast, gastrointestinal, prostate, brain, and others, the review highlighted spirituality and religion’s significant role in improving cancer patients’ well-being. Across different cancers, greater spiritual well-being and religious coping were consistently associated with an improved quality of life, reduced distress, enhanced coping, and better treatment outcomes. Interventions such as mindfulness therapy, yoga, and religious coping strategies positively impact patients’ spiritual and emotional well-being. Conclusions: This review highlights the vital role of spirituality and religion in cancer care. Integrating these aspects into patient plans offers comfort and support throughout treatment. Healthcare providers should prioritize spiritual support to enhance patient well-being and optimize outcomes.

Background and objectives: The global burden of non-communicable diseases like obesity and cancer, particularly colorectal cancer (CRC), is increasing. The present study aimed to investigate the association between CRC location (proximal vs. distal) and patient demographic factors including age, sex, and BMI, as well as cancer stage at diagnosis. Materials and Methods: In this cross-sectional study, data from 830 patients diagnosed with CRC were analyzed. The variables included age, sex, weight, height, BMI, cancer location, and cancer stage at diagnosis. Patients were stratified into three age groups and three BMI categories, and we analyzed the association between cancer location and these variables using Chi-squared tests and multivariate logistic regression. Results: The rectum and ascending colon were the most common locations of malignant neoplasms. No statistically significant differences in cancer location across age groups were observed. Significant differences were found in the BMI across age groups, particularly in the normal weight and overweight categories. Normal weight and obese patients had a higher proportion of Stage 3 and Stage 4 cancers. Obesity emerged as a significant predictor for rectal cancer in a multivariate logistic regression analysis, with an odds ratio of 1.56. However, no significant associations were found between cancer location and other factors like age, gender, or cancer stage. Conclusions: Our study revealed that normal weight and obese patients had a higher proportion of Stage 3 and Stage 4 cancers, with obesity emerging as a significant predictor for rectal cancer. It is important to note that while obesity was found to be a significant predictor for rectal cancer, the development and location of colorectal cancer is likely influenced by various factors beyond those studied here. Therefore, further research is needed to investigate the roles of other potential risk factors, like loss of SIRT6 and adipose tissue homeostasis. Additionally, inflammation associated with microbiota in the colorectal mucosa, systemic gene expression, and visceral obesity may also play important roles in the development and progression of colorectal cancer. Understanding these intricate relationships is crucial for better screening, disease prognosis, and management strategies.

The predictions on the influence of the SARS-CoV-2 pandemic on access to medical services in Romania predicted a 35% drop in oncological hospitalizations in 2020 compared to the previous decade, raising the hypothesis that patients with colorectal cancer can become indirect victims of the ongoing pandemic. Therefore, the aim of the current research was to observe how the COVID-19 pandemic influenced colorectal cancer surgery in Romania, to determine the level of addressability towards specialized care, to compare the cancer staging between the pandemic and pre-pandemic periods, and to observe the risk factors for disease progression. This retrospective study was spread over three years, respectively, from March 2019 to March 2022, and included a total of 198 patients with a history of colorectal cancer surgery. It was decided to perform a parallel comparison of 2019, 2020, and 2021 to observe any significant changes during the pandemic. Our clinic encountered a significant decrease in all interventions during the pandemic; although the number of CRC surgeries remained constant, the cases were more difficult, with significantly more patients presenting in emergency situations, from 31.3% in 2019 to 50.0% in 2020 and 57.1% in 2021. Thus, the number of elective surgeries decreased significantly. The proportion of TNM (tumor-node-metastasis) staging was, however, statistically significant between the pre-pandemic and pandemic period. In 2019, 13.3% of patients had stage IIa, compared with 28.8% in 2020 and 13.1% in 2021. Similarly, the proportion of very advanced colorectal cancer was higher during the pandemic period of 2020 and 2021 (12.0% in 2019 vs. 12.5% in 2020 and 25.0% in 2021), which was represented by a significantly higher proportion of patients with bowel perforation. Patients with an advanced TNM stage had a 6.28-fold increased risk of disease progression, followed by lymphovascular invasion (HR = 5.19). However, the COVID-19 pandemic, represented by admission years 2020 and 2021, did not pose a significant risk for disease progression and mortality. In-hospital mortality during the pandemic also did not change significantly. After the pandemic restrictions have been lifted, it would be advisable to conduct a widespread colorectal cancer screening campaign in order to identify any instances of the disease that went undetected during the SARS-CoV-2 pandemic.

Background: Metabolically associated fatty liver disease (MASLD) constitutes a major burden. Glucagon-like peptide-1 agonists (GLP-1) could improve hepatic steatosis as well as weight loss. However, the effect of GLP-1 agonists on patients with and without diabetes and the effect of newer drugs (dual and triple agonists) are unclear. Objective: To investigate the effect of GLP-1 agonists, including dual and triple agonists, in patients with metabolic-associated liver steatosis and steatohepatitis, while exploring their effect on patients with and without type 2 diabetes. Methods: We searched PubMed, Scopus, and Web of Science in October 2025 for randomized parallel controlled trials that investigated the effect of GLP-1 agonists in patients with MASLD or metabolic-associated steatohepatitis (MASH). We assessed the quality of the included studies using Cochrane ROB2. We performed the analysis using RevMan 5.4. We performed subgroup analysis based on the status of diabetes, the control group, and the class of GLP-1 agonist (single, dual, or triple). Results: We included twenty studies. Compared to the control group, GLP-1 agonists were associated with a statistically significant increase in the resolution of MASH without worsening fibrosis (RR 3.03, p < 0.0001) and at least one stage of liver fibrosis without the worsening of MASH compared to the control group (RR: 1.45, p < 0.00001). GLP-1 agonists were associated with a statistically significant weight reduction (SMD −1.11, p < 0.0001), glycosylated hemoglobin (SMD −0.81, p < 0.00001), levels of aspartate aminotransferase (SMD −0.48, p = 0.008), and alanine aminotransferase (SMD −0.54, p = 0.008). However, in patients without type 2 diabetes, GLP-1 agonists had no significant effect on weight loss (SMD −0.97, p = 0.12) or improvement in fibrosis (RR 1.54, p = 0.24). There was a statistically significant increase in the overall adverse events (RR 1.10, p < 0.00001), while there was no significant difference in serious adverse events (p = 0.35). Conclusions: GLP-1 agonists improved liver fibrosis, steatohepatitis, weight loss, HbA1c, and liver enzymes in patients with MASLD or MASH. Overall, GLP-1 agonists were associated with a significantly higher risk of adverse events compared to the control, while serious adverse events were comparable between both groups. There was no significant effect on weight loss or improvement in fibrosis in patients without type 2 diabetes. However, there was a limited number of studies in this population. Thus, further research is needed before recommendations can be made for this subgroup.

The occurrence of pneumorrhachis (PR), defined as the presence of air within the spinal canal, presents a complex clinical picture with diverse etiological factors. We report an exceedingly rare case of PR arising from locally advanced rectal cancer accompanied by a pre-sacral abscess. This report aims to enhance awareness and understanding of rare causes of PR within the medical community, particularly among surgeons engaged in emergency procedures. The patient survived the acute phase of the disease through multiple surgical interventions and admission to the intensive care unit, but succumbed to cardiovascular complications three weeks later. We also offer a brief review of the literature concerning PR originating from the colorectal lumen.

Background: Laryngeal cancer constitutes a major burden. Accurate staging is important to determine the optimal treatment approach. However, a head-to-head comparison of diagnostic performance between CT and MRI in patients with laryngeal cancer is lacking. Furthermore, the performance of CT and MRI in detecting the invasion of different laryngeal structures is yet to be determined. Objective: To compare the diagnostic performance of CT and MRI in patients with laryngeal cancer. Methods: We searched PubMed, Scopus, and Web of Science in November 2025 for cohort studies that compared both index tests (CT and MRI) to histopathological examination of laryngeal cancer. We assessed the quality of the included studies using the QUADAS 2 tool. A bivariate meta-analysis was performed using R and RevMan software to compare pooled sensitivity and specificity, with summary receiver operating characteristic (SROC) curves generated for each outcome. Results: We included eight studies. The pooled data showed that CT was significantly less sensitive compared to MRI in detecting invasion of the thyroid cartilage with an absolute difference of −0.43 (95% CI −0.59 to −0.26), cricoid cartilage −0.65 (95% CI −1.14 to −0.15), paraglottic space −0.5 (95% CI −0.68 to −0.32), and anterior commissure −0.48 (95% CI −0.1 to −0.86). Specificity was similarly high for both modalities across all structures. For arytenoid cartilage and epiglottis invasion, MRI showed a non-significant trend towards higher sensitivity. Summary receiver operating characteristic (SROC) curves indicated superior overall diagnostic accuracy for MRI. In T-staging, MRI consistently demonstrated a lower rate of understaging compared to CT across five studies. Conclusions: MRI had superior diagnostic performance compared to CT in detecting laryngeal cartilage and deep space invasion; it had significantly higher sensitivity, comparable specificity, and lower risk of understaging, thus supporting the use of MRI for accurate pretreatment T-staging. However, given the limited number of studies, the results should be interpreted with caution, and further studies are needed to confirm our findings.